Tendai Mugwagwa

10PUBLICATIONS
24CO-AUTHORS
Predictive and prognostic markersPanel data analysisEconomic models and forecastingTime-series analysisPreventative health care
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 06, 2026
Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review.

|Jan 21, 2026
Cost-effectiveness and return on investment of 20-valent pneumococcal conjugate vaccine use among adults in England: analysis from the societal perspective.

Diana Mendes, Ahuva Averin, Mark Atwood

|Oct 24, 2025
Nirmatrelvir/ritonavir treatment for COVID-19: an economic value systematic literature review.

Tendai Mugwagwa, José Marcano Belisario, Louise Hartley

|Dec 20, 2024
Cost-effectiveness of outpatient COVID-19 antiviral treatment with nirmatrelvir/ritonavir versus usual care in Swedish patients with various risk factors.

Fredrik Nilsson, Martina Aldvén, Christian Gerdesköld Rappe

|Nov 19, 2024
Estimating hospitalization costs for Health Technology Appraisals (HTA) in England: a systematic literature review and best practice framework.

Kelli Zhao, Diana Mendes, Rebecca Butfield

|Oct 13, 2022
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.

Diana Mendes, Ahuva Averin, Mark Atwood

Pageof 2

Frequent Collaborators

5 joint publications

Diana Mendes

4 joint publications

James Campling

4 joint publications

Andrew Vyse

3 joint publications

Derek Weycker